• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1.5 Contact Hour(s)

    Release Date

    Monday, December 31, 2018

    Offline Date

    Monday, July 15, 2019

    ACPE Expiration Date

    Friday, July 16, 2021

    Target Audience

    Pharmacist, Nurse

    Cost

    $0.00

    • Overview

      The promise of the immune system in helping to treat cancer has finally become a reality in the past few years. The immune system is designed to differentiate between normal cells  foreign cells.  To do this, it uses “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response.  Cancer cells often may look like normal cells and may evade the immune system recognition.  An important molecule in this process is CTLA4 and thus a CTLA4 antagonist has been developed to help T cells recognize cancer cells better.  Once the T cells finds the cancer cell another checkpoint is the molecule PD-1 on the T cell which binds to the PD-L1 receptor on the Cancer cell which will cause destruction of the T cell.  This appears to be a major reason why T cells have difficulty killing cancer cells.  Both PD-1 and PD-L1 inhibitors have now been established and have good effects in a variety of cancers including melanoma of the skin, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers,  Hodgkin lymphoma, bladder cancer, non-small cell lung cancer, and Merkel cell skin cancer.

      Since these drugs inhibit normal checkpoints the problem is they may allow T cells to now recognize normal cells as being foreign, which can lead to serious side effects commonly behaving as autoimmune disease.

      The newest agents in the immunology-oncology field are Chimeric Antigen Receptor T cells, in which the patients own T cells are genetically modified to produce a receptor for a target on the T cell.  Currently approved agents express CD19 and are approved for relapsed/refractory ALL and DLBCL.  These are extremely exciting agents which may have the potential for long term remission of cancer.  One problem is if the T cells expand too rapidly they release cytokines, called “Cytokine Storm” which can be life threatening. Thus it is critical pharmacists have a good understanding of the mechanisms and adverse events associated with all of these therapies and a good understanding of how to manage the side effects.

      Handouts

      • Slide Document :   18099H01_4pp.pdf
      • Slide Document :   18099H01_2pp.pdf

      Financial Support By

      Merck & Co., Inc
    • Pharmacist

      Understand the pharmacist's role in communicating recommendations in caring for patients on these agents
      Describe the symptoms of the adverse events of these agents and potential management strategies
      Describe the mechanism of action of these immunologic agents
      Identify current FDA approved PD-1, PD-L1 and CTLA4 Inhibitors as well as Chimeric Antigen T cells and their indications and their place in therapy.

      Nurse

      Understand the pharmacist's role in communicating recommendations in caring for patients on these agents
      Describe the mechanism of action of these immunologic agents
      Identify current FDA approved PD-1, PD-L1 and CTLA4 Inhibitors as well as Chimeric Antigen T cells and their indications and their place in therapy.
      Describe the symptoms of the adverse events of these agents and potential management strategies
    • Activity Type

      Application

      CE Broker

      20-659070

      Universal Activity Number

      Pharmacist 0798-0000-18-099-H01-P
      Nurse 0798-0000-18-099-H01-P

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

    • Faculty

      David  Frame, PharmD
      Assistant Professor, University of Michigan College of Pharmacy

    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).